NeoGenomics Reports Second Quarter 2026 Financial Results

Current Report Filed with Financial Results Announcement

NeoGenomics, Inc., incorporated in Nevada and headquartered in Fort Myers, Florida, announced its second quarter 2026 financial results through a current report filed with the Securities and Exchange Commission on July 28, 2026. The announcement was made via press release, with Abhishek Jain, the company's Chief Financial Officer, signing the disclosure. The filing follows standard regulatory procedures for quarterly earnings announcements and provides the investment community with timely insight into the company's operational and financial performance during the second quarter of fiscal 2026.

The company operates in the genomic testing and cancer diagnostics sector, serving healthcare providers and patients requiring specialized laboratory analysis and genetic testing services. NeoGenomics maintains its primary operations facility in Fort Myers, Florida, and trades on The Nasdaq Stock Market LLC under the ticker symbol NEO. The quarterly disclosure mechanism allows investors to monitor the company's progress throughout the fiscal year and assess its performance trajectory relative to prior periods and market expectations.

Regulatory Disclosure Framework and Filing Details

The announcement was structured as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, with the press release incorporated as an exhibit to the filing. This reporting mechanism ensures that material information regarding the company's financial condition and results of operations reaches investors simultaneously and in a transparent manner. The disclosure explicitly notes that the press release information is furnished rather than filed, which affects its regulatory treatment under securities laws but does not diminish its importance as a disclosed communication to the investment community.

NeoGenomics clarified in the filing that the furnished information shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Additionally, the disclosure will not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as expressly set forth by specific reference in such filing. This clarification is standard practice for earnings releases furnished as exhibits to regulatory filings and reflects the company's compliance with applicable securities regulations.

Quarterly Performance Disclosure Structure

The filing structure indicates that NeoGenomics provided comprehensive operational and financial information within the accompanying press release. The company disclosed financial results, operational metrics, and performance indicators relevant to investors' assessment of the company's business trajectory during the six-month period ending in the second quarter of 2026. The detailed press release, identified as Exhibit 99.1 in the current report, serves as the primary vehicle for communicating the company's quarterly performance to shareholders and the broader investment community.

The disclosure format follows standard practice for publicly traded companies reporting quarterly earnings, with the press release delivering consolidated financial statements, management commentary, and performance analysis. By issuing a comprehensive press release alongside the regulatory filing, NeoGenomics provided investors with contextual information regarding operational developments, market conditions, and management's perspective on the company's financial position and near-term outlook during the second quarter of 2026.

Company Overview and Market Position

NeoGenomics operates as a specialized genomic testing and cancer diagnostics laboratory, providing services to healthcare providers and medical professionals nationwide. The company's Fort Myers, Florida headquarters serves as the operational and administrative center for its business activities. With a Commission File Number of 001-35756 and an Internal Revenue Service Employer Identification Number of 74-2897368, NeoGenomics maintains full regulatory compliance as a publicly traded entity on The Nasdaq Stock Market.

The company's business model centers on providing accurate genomic analysis and cancer-focused laboratory testing services, which have become increasingly important in precision medicine and personalized cancer treatment planning. By specializing in genomic testing, NeoGenomics addresses a growing market segment within the broader healthcare diagnostics industry, where demand for detailed genetic and molecular analysis continues to expand as healthcare providers and patients seek more targeted and effective treatment approaches.

Investor Access to Detailed Financial Information

The press release furnished with the filing provides investors with detailed quantitative and qualitative information regarding NeoGenomics' second quarter 2026 performance. The company did not disclose specific financial figures, revenue metrics, earnings per share, or other quantitative performance indicators in the current report itself, as these details were contained within the accompanying press release exhibit. Investors seeking comprehensive financial data, management guidance, and operational analysis would need to review the full press release to obtain complete insight into the company's quarterly results.

The company's approach to earnings disclosure reflects standard practice in the genomics and laboratory services sector, where detailed financial results, analysis of revenue trends, operating expenses, and strategic developments are typically communicated through comprehensive press releases. This structure allows management to provide context and interpretation of financial results alongside the raw data, enabling investors to understand not only the numbers but also the operational and market factors influencing the company's financial performance during the quarter.

Stock Information and Trading Details

NeoGenomics common stock trades on The Nasdaq Stock Market LLC under the ticker symbol NEO, with each share having a par value of $0.001. The stock's trading history and price movements are available through Nasdaq's official data and financial platforms, allowing investors to track the company's market valuation and performance relative to other companies in the genomics and laboratory services sector. The immediate share price impact of the quarterly results announcement was not clear from available public information contained within the current report filing.

As a Nasdaq-listed company, NeoGenomics is subject to all applicable listing standards, disclosure requirements, and corporate governance rules established by Nasdaq and the Securities and Exchange Commission. The company's status as a publicly traded entity requires ongoing compliance with financial reporting obligations, insider trading regulations, and other securities law requirements designed to protect investors and maintain market integrity.

Executive Officer Verification and Filing Authority

Abhishek Jain, serving as Chief Financial Officer of NeoGenomics, Inc., signed the current report on July 28, 2026, pursuant to the requirements of the Securities Exchange Act of 1934. As the senior financial officer of the company, Jain bore responsibility for certifying the accuracy and timeliness of the earnings announcement and ensuring that all material information regarding the company's financial condition and results of operations was properly disclosed to investors. His signature on the filing represents the company's official authentication of the quarterly results announcement.

The CFO's involvement in signing the earnings disclosure reflects the significance and regulatory importance of quarterly financial reporting in the securities markets. By personally signing the filing, Jain confirmed that the company had exercised appropriate diligence in preparing and reviewing the quarterly results before release to the investment community, and that the information contained in the press release accurately represented the company's financial and operational performance during the second quarter of 2026.

Emerging Growth Company Status and Accounting Standards

NeoGenomics did not indicate in the filing that it qualifies as an emerging growth company under the definitions provided in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. This classification is relevant because emerging growth companies are eligible for certain scaled disclosure requirements and extended transition periods for compliance with new or revised financial accounting standards. By not selecting the emerging growth company checkbox, NeoGenomics indicated that it either does not meet the criteria for this designation or has chosen not to rely on the exemptions and accommodations available to emerging growth companies.

The company's accounting standards compliance and financial reporting obligations therefore follow the standard requirements applicable to well-established public companies. This status indicates that NeoGenomics has reached a level of scale, market capitalization, or annual revenue that places it beyond the emerging growth company classification, reflecting the company's maturity as a publicly traded entity in the genomics and laboratory services industry.

Xbrl Data and Interactive Disclosure Format

The filing included a Cover Page Interactive Data File embedded within the Inline XBRL document, designated as Exhibit 104. XBRL (eXtensible Business Reporting Language) format allows financial data and information to be tagged and structured in a machine-readable format, facilitating analysis by investors, financial analysts, and research platforms. This interactive data file enhances the accessibility and analytical utility of the company's financial disclosures by enabling automated data extraction and comparison across time periods and companies.

The inclusion of XBRL-formatted data reflects the SEC's ongoing efforts to standardize corporate financial reporting and enhance transparency in the securities markets. By providing financial information in both traditional narrative and interactive data formats, NeoGenomics facilitated wider accessibility to its quarterly results and supported various analytical methodologies employed by professional investors and financial research firms seeking to evaluate the company's financial performance and trends.